Lonza Group AG Share Price OTC Markets

Equities

LZAGY

US54338V1017

Biotechnology & Medical Research

Delayed OTC Markets 08:30:42 20/06/2024 pm IST 5-day change 1st Jan Change
53.68 USD -0.45% Intraday chart for Lonza Group AG -0.33% +27.54%

Financials

Sales 2024 * 666.67Cr 748.66Cr 63TCr Sales 2025 * 765.26Cr 859.37Cr 72TCr Capitalization 3.41TCr 3.83TCr 3,20500Cr
Net income 2024 * 88Cr 99Cr 8.31TCr Net income 2025 * 110.5Cr 124.09Cr 10TCr EV / Sales 2024 * 5.55 x
Net Debt 2024 * 284.91Cr 319.95Cr 27TCr Net Debt 2025 * 344.56Cr 386.94Cr 32TCr EV / Sales 2025 * 4.91 x
P/E ratio 2024 *
38.5 x
P/E ratio 2025 *
30.7 x
Employees 18,000
Yield 2024 *
0.96%
Yield 2025 *
1.12%
Free-Float 96.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.45%
1 week-0.33%
Current month-0.96%
1 month-7.91%
3 months-7.02%
6 months+35.52%
Current year+27.54%
More quotes
1 week
52.76
Extreme 52.76
54.24
1 month
52.23
Extreme 52.23
57.49
Current year
40.14
Extreme 40.1425
62.87
1 year
34.19
Extreme 34.19
64.88
3 years
34.19
Extreme 34.19
86.31
5 years
31.93
Extreme 31.93
86.31
10 years
10.19
Extreme 10.19
86.31
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 25/17/25
Director of Finance/CFO 52 01/21/01
Chief Operating Officer 55 01/22/01
Members of the board TitleAgeSince
Director/Board Member 63 16/14/16
Director/Board Member 66 16/14/16
Director/Board Member 58 05/22/05
More insiders
Date Price Change Volume
20/24/20 53.68 -0.45% 5 171
18/24/18 53.92 +0.90% 42,618
17/24/17 53.44 -0.58% 54,888
14/24/14 53.75 -0.20% 51,668
13/24/13 53.86 -0.37% 24,550

Delayed Quote OTC Markets, June 20, 2024 at 08:30 pm IST

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (55.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (17.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.4%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.4%); - other (3.5%). Net sales are distributed geographically as follows: Switzerland (17.4%), Europe (31.7%), the United States (31.8%), the Americas (3.2%), Japan (8.1%), Asia (7.5%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
473.4 CHF
Average target price
586 CHF
Spread / Average Target
+23.79%
Consensus